On Thursday's edition of Market Checkup, The Motley Fool's health-care focused show for investors, Fool health-care analyst David Williamson sheds some light on what's driving the biggest movers in the health-care space today.

Shares of Ariad Pharmaceuticals popped 8% today on word from British newspapers that Eli Lilly , and possibly GlaxoSmithKline , were interested in buying the biotech. To David however, the story just doesn't add up. In this segment, he looks at why the deal wouldn't make sense for Eli Lilly or Glaxo, and why he isn't putting a lot of credence behind these reports.

So what's the best way for investors to play the biotech space?
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


The article Thursday: 1 Big Winner in Health Care originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Introduction to ETFs

The basics of Exchange Traded Funds and why ETFs are hot.

View Course »

Portfolio Basics

What are stocks? Learn how to start investing.

View Course »

Add a Comment

*0 / 3000 Character Maximum